MedPark Regeneration First

ABOUT US

  • Vision

  • History

  • Global Network

Regenerative medical solution provider

MedPark
VISION 2025

IPO

KOREA
No.1

AsiaPacific
No.1

Global
TOP10

First in Korea and Asia Completed clinical and commercialization,
acquiredglobal certification
MedPark's dream is the future of regenerative medical.

History

20
21
  • Obtained the European CE mark for S1
  • Selection of 2021 K-Unicorn
20
  • Obtained World’s first European CE simultaneously for
    • - Xenograft(Bovine, Porcine)
    • - Collagen membrane
  • S1 global IP patent application and registration
  • MFDS permission for bone graft for medical use
19
  • Selection of hidden champion
  • Supply to the world's No. 1 implant manufacturer
  • Completion of 3rd factory and Seoul Research Institute
  • Winning the 2019 Korea Small and Medium Business Regulatory Innovation Award
17~2018
  • Incorporation transition(MedPark Co., Ltd.)
  • Minister of SMEs and Startups Awarded
  • Completion of 2nd factory (500 million free cash support from Busan)
  • Selection of government tasks for convergence of material parts technology
10~2015
  • Established MedPark
  • Achieved $1 million export
  • Completion of company builiding
  • Establishment of China (Qingdao) corporation

MedPark Biomedical

Global Network + Innovative technical skills =Global brand leap forward

Securing over 200 global dealer channel networks

  • Europe: World's first CE certification 3 products acquired and commercialized
  • Main bases by continent + China and global dealer channels
  • Greater China/North America: CFDA/FDA approval in progress
  • Asia-Pacific/Middle East: Completion of national approval and commercialization
  • Latin America: Permits in progress by country
  • Partnering with and supplying global major implant manufacturers